Evidence for viral clearance in females already infected with HPV
STUDY DETAILS					SUMMARY
Study	Vaccine	Study Design	Participants	Summary of Key Findings	Level of Evidence	Quality
HPV009 (101)	Cervarix™	Randomized trial To determine whether vaccination increases the rate of viral clearance in women already infected with HPV	Females 18 to 25 years =2189	No evidence of increased viral clearance at 6 or 12 months in the group who received HPV vaccine compared with the control group. Clearance rates for HPV-16/18 infections: -at 6 months: 33.4% (82/248) in the HPV vaccine group and 31.6% (95/298) in the control group (vaccine efficacy for viral clearance, 2.5%; 95% CI,−9.8%to 13.5%). -at 12 months: 48.8% (86/177) in the HPV vaccine group and 49.8% (110/220) in the control group (vaccine efficacy for viral clearance,−2.0%;95%confidence interval,−24.3%to 16.3%).	Level I	Good